cancer of unknown primary
Cancer Dx Firm C2i Genomics Raises $100M in Financing
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit
Premium
Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
NGS-Based Profiling May Guide Treatment for Patients With Cancers of Unknown Primary
Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.
Twist Bioscience, Neogene Therapeutics Partner to Develop Personalized CAR T Cells, TCR Therapies
The companies will combine Neogene's expertise in targeting tumor neoantigens with Twist's DNA synthesis platform and product lines.